Recent performance snapshot Qiagen (QGEN) has drawn investor attention after recent trading, with the share price at US$41.21 and a 1-day return of about a 4% decline, alongside a past week return ...

Qiagen NV CEO Thierry Bernard said the company is working with Moelis & Co. and Goldman Sachs to review its strategic alternatives. "We are no ...

Qiagen ( (QGEN)) has issued an announcement. QIAGEN has disclosed a managers’ transaction involving Roland Sackers, a member of its managing body, under market abuse regulations. The transaction ...

An update from Qiagen ( (QGEN)) is now available. Qiagen has disclosed a managers’ transaction under EU market abuse regulations involving supervisory board member Eva van Pelt. She received a grant ...

Fintel reports that on March 13, 2026, Deutsche Bank upgraded their outlook for Qiagen N.V. (NYSE:QGEN) from Hold to Buy.

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...

Consistent with its strategy of expanding in the international arena, Qiagen (QGEN) recently entered into a co-marketing agreement with China's largest independent laboratory network KingMed ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the ...

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsThierry Bernard - CEO, MD & Member ...